Eupraxia Pharmaceuticals (NASDAQ:EPRX) Releases Earnings Results, Beats Expectations By $0.02 EPS

Eupraxia Pharmaceuticals (NASDAQ:EPRX) issued its quarterly earnings results on Tuesday. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.02, Zacks reports.

Eupraxia Pharmaceuticals Stock Up 0.6%

Shares of NASDAQ:EPRX traded up $0.04 during trading on Tuesday, reaching $6.70. 181,022 shares of the stock traded hands, compared to its average volume of 269,418. The stock has a market cap of $435.63 million, a P/E ratio of -6.38 and a beta of 1.08. The company has a debt-to-equity ratio of 0.02, a quick ratio of 19.31 and a current ratio of 19.31. The stock has a 50-day moving average of $6.40 and a two-hundred day moving average of $7.20. Eupraxia Pharmaceuticals has a 52-week low of $5.04 and a 52-week high of $9.32.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in EPRX. Vivo Capital LLC bought a new stake in shares of Eupraxia Pharmaceuticals in the 3rd quarter worth $7,965,000. Ikarian Capital LLC purchased a new position in shares of Eupraxia Pharmaceuticals in the fourth quarter worth $4,606,000. Squadron Capital Management LLC bought a new position in shares of Eupraxia Pharmaceuticals during the fourth quarter valued at $3,775,000. Velan Capital Investment Management LP bought a new position in shares of Eupraxia Pharmaceuticals during the third quarter valued at $2,077,000. Finally, Alyeska Investment Group L.P. bought a new position in shares of Eupraxia Pharmaceuticals during the third quarter valued at $1,475,000.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on EPRX shares. Oppenheimer started coverage on shares of Eupraxia Pharmaceuticals in a research note on Thursday, June 25th. They set an “outperform” rating and a $17.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of Eupraxia Pharmaceuticals in a report on Monday, May 4th. Cantor Fitzgerald reissued an “overweight” rating on shares of Eupraxia Pharmaceuticals in a research report on Wednesday, July 15th. Wall Street Zen downgraded Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Finally, Zacks Research upgraded Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.